title: Farnesyltransferase inihibitors in hematologic malignancies.
abstract: Farnesyltransferase inhibitors (FTIs) inhibit certain cellular signal transduction pathways, and are being evaluated for activity in hematologic malignancies. Tipifarnib and lonafarnib are orally available FTIs that are active against a variety of targets and inhibit several pathways involved in the pathogenesis of hematologic malignancies. FTIs have demonstrated activity in a variety of hematologic diseases, including acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and multiple myeloma. This article reviews the clinical experience with tipifarnib and lonafarnib in the treatment of hematologic malignancies.
authors.affiliation: Department of Hematology, Hotel Dieu, Place Alexis Ricordeau, 44093 NANTES CEDEX 01, France. jean-luc.harousseau@univ-nantes.fr
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Harousseau
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D004791:Enzyme Inhibitors / Q000097:blood / Q000627:therapeutic use*; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors* / Q000097:blood / Q000378:metabolism; D019337:Hematologic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D010880:Piperidines / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D015363:Quinolones / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D015398:Signal Transduction; D003986:Dibenzocycloheptenes
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D051231:Farnesyltranstransferase; D010880:Piperidines; D011725:Pyridines; D015363:Quinolones; C115354:lonafarnib; D003986:Dibenzocycloheptenes; C402769:tipifarnib